학술논문

Effective preclinical treatment of KRAS mutant lung cancers with a combination of MLN0128, an investigational novel mTORC1/2 inhibitor, and a selective MEK inhibitor
Document Type
Journal
Source
MOLECULAR CANCER THERAPEUTICS; NOV 2013, 12 11, 1p. Supplement: S
Subject
Language
English
ISSN
15388514